Get started
Ultragenyx Pharmaceutical Inc.Ultragenyx Pharmaceutical Inc.Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RARE chart


Full chart

RARE upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.01 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.46 USD
Net income (FY)
‪−606.64 M‬ USD
Revenue (FY)
‪434.25 M‬ USD
Shares float
‪83.35 M‬
Beta (1Y)
0.98

Employees


Employees (FY)
‪1.28 K‬
Change (1Y)
−35 −2.67%
Revenue / Employee (1Y)
‪340.32 K‬ USD
Net income / Employee (1Y)
‪−475.42 K‬ USD

About Ultragenyx Pharmaceutical Inc.


Sector
Health Technology
CEO
Emil D. Kakkis
Headquarters
Novato
Website
ultragenyx.com
Founded
2010
FIGI
BBG001RWPDW6
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RARE news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RARE is 44.22 USD — it has increased by 1.73% in the past 24 hours. Watch Ultragenyx Pharmaceutical Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ultragenyx Pharmaceutical Inc. stocks are traded under the ticker RARE.
RARE stock has fallen by −5.25% compared to the previous week, the month change is a −1.54% fall, over the last year Ultragenyx Pharmaceutical Inc. has showed a −3.79% decrease.
We've gathered analysts' opinions on Ultragenyx Pharmaceutical Inc. future price: according to them, RARE price has a max estimate of 140.00 USD and a min estimate of 48.00 USD. Watch RARE chart and read a more detailed Ultragenyx Pharmaceutical Inc. stock forecast: see what analysts think of Ultragenyx Pharmaceutical Inc. and suggest that you do with its stocks.
RARE reached its all-time high on Dec 24, 2020 with the price of 179.65 USD, and its all-time low was 31.52 USD and was reached on Oct 24, 2023. View more price dynamics on RARE chart.
See other stocks reaching their highest and lowest prices.
RARE stock is 3.73% volatile and has beta coefficient of 0.98. Track Ultragenyx Pharmaceutical Inc. stock price on the chart and check out the list of the most volatile stocks — is Ultragenyx Pharmaceutical Inc. there?
Today Ultragenyx Pharmaceutical Inc. has the market capitalization of ‪4.08 B‬, it has decreased by −8.00% over the last week.
Yes, you can track Ultragenyx Pharmaceutical Inc. financials in yearly and quarterly reports right on TradingView.
Ultragenyx Pharmaceutical Inc. is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
RARE earnings for the last quarter are −1.40 USD per share, whereas the estimation was −1.48 USD resulting in a 5.66% surprise. The estimated earnings for the next quarter are −1.37 USD per share. See more details about Ultragenyx Pharmaceutical Inc. earnings.
Ultragenyx Pharmaceutical Inc. revenue for the last quarter amounts to ‪139.49 M‬ USD, despite the estimated figure of ‪135.28 M‬ USD. In the next quarter, revenue is expected to reach ‪143.29 M‬ USD.
RARE net income for the last quarter is ‪−133.52 M‬ USD, while the quarter before that showed ‪−131.60 M‬ USD of net income which accounts for −1.46% change. Track more Ultragenyx Pharmaceutical Inc. financial stats to get the full picture.
No, RARE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has ‪1.28 K‬ employees. See our rating of the largest employees — is Ultragenyx Pharmaceutical Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ultragenyx Pharmaceutical Inc. EBITDA is ‪−501.06 M‬ USD, and current EBITDA margin is −125.09%. See more stats in Ultragenyx Pharmaceutical Inc. financial statements.
Like other stocks, RARE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ultragenyx Pharmaceutical Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ultragenyx Pharmaceutical Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ultragenyx Pharmaceutical Inc. stock shows the strong sell signal. See more of Ultragenyx Pharmaceutical Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.